Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 5/20 | 0.32 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9847148 | 0.87 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL2468781 | 0.85 | ATM (0.50) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL1325949 | 0.83 | ATM (0.48) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL20875236 | 0.82 | ATM (0.60) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL8669692 | 0.82 | ATM (0.60) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL20913247 | 0.82 | ATM (0.60) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL4448964 | 0.81 | ATM (0.47) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL297601 | 0.80 | ATM (0.46) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL25174772 | 0.80 | ATM (0.64) | ATMHCAR2MAPTRAB9ANPSR1 | |
| SCHEMBL20875241 | 0.80 | ATM (0.58) | ATMHCAR2MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9823520-B2 | Liquid crystal display apparatus and method for manufacturing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-11-21 | — | — | US | claimed |
| US-20150168763-A1 | LIQUID CRYSTAL DISPLAY APPARATUS AND METHOD FOR MANUFACTURING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2015-06-18 | — | — | US | claimed |
| US-8614278-B2 | Silicone acrylate hybrid composition and method of making same | DOW CORNING CORPORATION (US) | 2013-12-24 | — | — | US | claimed |
| EP-2599847-A1 | A Silicone Acrylate Hybrid Composition and Method of Making Same | Dow Corning Corporation (US) | 2013-06-05 | — | — | EP | claimed |
| EP-2024406-B1 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2012-08-01 | — | — | EP | claimed |
| US-20120114737-A1 | SILICONE ACRYLATE HYBRID COMPOSITION AND METHOD OF MAKING SAME | DOW SILICONES CORPORATION | 2012-05-10 | — | — | US | claimed |
| US-20090196911-A1 | Silicone Acrylate Hybride Composition and Method Of Making Same | DOW SILICONES CORPORATION | 2009-08-06 | — | — | US | claimed |
| EP-2024406-A2 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING CORPORATION (US) | 2009-02-18 | — | — | EP | claimed |
| WO-2007145996-A9 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2008-02-14 | — | — | WO | claimed |
| WO-2007145996-A2 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING CORPORATION (US) | 2007-12-21 | — | — | WO | claimed |
| EP-4395749-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-02-04 | — | — | US | disclosed |
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-12-17 | — | — | US | disclosed |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-11-14 | — | — | US | disclosed |
| US-12121616-B2 | Transdermal therapeutic system for the transdermal administration of solifenacin | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-10-22 | — | — | US | disclosed |
| WO-2007145996-A9 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007145996-A2 | A SILICONE ACRYLATE HYBRID COMPOSITION | DOW CORNING CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007050580-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM WITH ACRYLATE OR METHACRYLATE FUNCTIONAL PRESSURE SENSITIVE ADHESIVE COMPOSITION | DOW CORNING CORPORATION (US) | 2007-05-03 | — | — | WO | disclosed |
| US-6013855-A | EXPOSING A METAL OR GLASS SURFACE TO A SILANATED POLYMER, E.G., POLYOXYETHYLENE GLYCOL, HYDROLYZING THE SILANE GROUP TO REACT WITH SURFACE HYDROXIDES, AND CURING; MEDICAL EQUIPMENT; STENTS; ANTICOAGULANTS; NONADHESION OF PROTEINS | UNITED STATES SURGICAL (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998005269-A1 | GRAFTING OF BIOCOMPATIBLE HYDROPHILIC POLYMERS ONTO INORGANIC AND METAL SURFACES | PURDUE RESEARCH FOUNDATION (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | PDE2A, PDE3A, PDE3B | ATM 2261/4885HCAR2 1840/4885MAPT 273/4885 |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | GUCY1A2, PDE2A, PDE3A | ATM 3671/4885HCAR2 1493/4885MAPT 155/4885 |
| US-20120114737-A1 | SILICONE ACRYLATE HYBRID COMPOSITION AND METHOD OF MAKING SAME | MMS19, CAD, ACR | ATM 254/4885HCAR2 1282/4885MAPT 2236/4885 |
| US-12121616-B2 | Transdermal therapeutic system for the transdermal administration of solifenacin | TPSB2, NTSR2, NTSR1 | ATM 3774/4885HCAR2 1074/4885MAPT 1291/4885 |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | GUCY1A2, MTHFD1, FPGS | ATM 3994/4885HCAR2 7/4885MAPT 380/4885 |
| US-20090196911-A1 | Silicone Acrylate Hybride Composition and Method Of Making Same | MMS19, CAD, ACR | ATM 331/4885HCAR2 1115/4885MAPT 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.